期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

一种新型的口服c-Met抑制剂PF-2341066可通过抗增殖和抗血管生成两种机制发挥抗肿瘤作用 被引量：1

An Orally Available Small-Molecule Inhibitor of c-Met,PF-2341066,Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms
下载PDF
导出
摘要 1文献来源 Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms [J]. Cancer Res, 2007, 67 （ 9 ） ： 4408 -4417.
作者 陆舜 江本元
机构地区 上海市肺部肿瘤临床医学中心 广东省人民医院肿瘤中心
出处 《循证医学》 CSCD 2010年第4期204-206,共3页 The Journal of Evidence-Based Medicine
关键词 肿瘤 治疗 PF-2341066 neoplasms therapy PF-2341066
分类号 R730.5 [医药卫生—肿瘤] R73-36 [医药卫生—肿瘤]
  • 相关文献

参考文献3

  • 1Soda M,Choi YL,Enomoto M,et al.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[J].Nature,2007,2(448):561-566.
  • 2Shaw AT,Yeap BY,Mino-kenudson M,et al.Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK[J].J Clin Oncol,2009,27(26):4247-4253.
  • 3Koivunen JP,Mermel C,Zejnullahu K,et al.EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer[J].Clin Cancer Res,2008,14(13):4275-4283.

同被引文献9

  • 1Ou S H. Crizotinib:a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond[J].Drug Des Devel Ther,2011.471-485.
  • 2Pieter D K,Douglas M A,Robert M. Fit-for-purpose development of the enabling route to crizotinib (PF-02341066)[J].Organic Process Research & Development,2011,(05):1018-1026.
  • 3Cui J J,Michelle T D,Hong S. Structure based drug design of crizotinib (PF-02341066),apotent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET)kinase and anaplastic lymphoma kinase (ALK)+[J].Journal of Medicinal Chemistry,2011,(18):6342-6363.
  • 4Henry J B,Brandon M L,Gregory R O. Design,synthesis,and anaplastic lymphoma kinase (ALK) inhibitory activity for a novel series of 2,4,8,22-tetraazatetracyclo[14.3.1.13,7.19,13]docosa-1 (20),3 (22),4,6,9 (21),10,12,16,18-nonaene Macrocycles[J].Journal of Medicinal Chemistry,2012,(01):449-464.
  • 5Cui J J. Enantiomerically pure aminoheteroaryl compounds as proteinkinaseinhibitors[P].US,20060046991Al,2006.
  • 6Emre M I,Milly J,Neal C J. Studies on synthetic approaches to 1H-and 2H-indazolyl derivatives[J].Journal of Organic Chemistry,2001,(12):4220-4226.doi:10.1021/jo005786y.
  • 7Walaa A E O,Juha P H,Osmo E O H. Synthesis of 8-hydroxyquinolines with amino and thioalkyl functionalities at position 4[J].Journal of Heterocyclic Chemistry,2008,(02):593-595.doi:10.1002/jhet.5570450247.
  • 8Kim M M,Ruck R T,Zhao D. Green iodination of pyrazoles with iodine/hydrogen peroxide in water[J].Tetrahedron Letters,2008,(25):4026-4028.doi:10.1016/j.tetlet.2008.04.082.
  • 9安康,关建宁,杨浩,侯雯,万嵘.达沙替尼合成工艺改进[J].精细化工中间体,2011,41(2):42-44. 被引量：5

引证文献1

二级引证文献1

循证医学
2010年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部